Supplementary Table 2 from Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients

MLA

Akseli Hemminki, et al. Supplementary Table 2 from Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients. Mar. 2023. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....069f9b7e301daa1007e9da01b242ea42&authtype=sso&custid=ns315887.

APA

Akseli Hemminki, Vincenzo Cerullo, Tuomo Alanko, Tima Joensuu, Leena Laasonen, Kaarina P. L. Partanen, Satu Kauppinen, Aila Karioja-Kallio, Sirkka-Liisa Holm, Elina Haavisto, Minna Oksanen, Kalevi Kairemo, Ann M. Leen, Ulrike Gerdemann, Saila K. Pesonen, Anna Kanerva, Tuuli Ranki, Lotta Kangasniemi, Iulia Diaconu, & Sari Pesonen. (2023). Supplementary Table 2 from Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients.

Chicago

Akseli Hemminki, Vincenzo Cerullo, Tuomo Alanko, Tima Joensuu, Leena Laasonen, Kaarina P. L. Partanen, Satu Kauppinen, et al. 2023. “Supplementary Table 2 from Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients,” March. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....069f9b7e301daa1007e9da01b242ea42&authtype=sso&custid=ns315887.